Insulin sensitivity and haemostatic factors in men at high and low cardiovascular risk

Journal of Internal Medicine

Volumn 246, Issue 5, 1999, Pages 489-495

  Agewall, Stefan ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Fibrinogen; Insulin resistance; Plasminogen activator inhibitor activity; Prothrombin fragment 1 + 2; Thrombin antithrombin factor; von Willebrand factor

Indexed keywords

ANTITHROMBIN; FIBRINOGEN; NEUTRAL INSULIN; PROTHROMBIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; FIBRINOLYSIS; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PRIORITY JOURNAL; RISK ASSESSMENT;

AGED; BLOOD COAGULATION FACTORS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FIBRINOLYSIS; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; RISK; RISK FACTORS;

EID: 0032732237     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1999.00543.x     Document Type: Article

References (38)

1. 1 Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction: the study of men born in 1913. N Engl J Med 1984; 311: 501-505.
2. 2 Kannel WB, Wolf PA, Castelli WP, D'Agostini RB. Fibrinogen and risk of cardiovascular disease. J Am Med Assoc 1987; 258: 1183-86.
3. 3 Jansson J-H, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-55.
4. 4 Hamsten A, Wiman B, DeFaire U, Blombäck M. Increased plasma levels of rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-63.
5. 5 Aznar J, Estelles A, Tormo G et al. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J 1988; 59: 535-41.
6. 6 Juhan-Vague I, Pyke SD, Alessi MC, Jespersen J, Haverkate F, Thompson SG. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. Circulation 1996; 94: 2057-63.
7. 7 Kienast J, Thompson SG, Raskino C et al. Prothrombin fragment 1+2 and thrombin antithrombin III complexes in patients with angina pectoris: relations to the presence and severity of coronary atherosclerosis. Thromb Haemostas 1993; 70: 550-53.
8. 8 Agewall S, Wikstrand J, Suurküla M, Tengborn L, Fagerberg B. Carotid artery wall morphology, hemostatic factors and cardiovascular disease: an ultrasound study in men at high and low risk for atherosclerotic disease. Blood, Coag Fibrinol 1994; 5: 895-904.
9. 9 Agewall S, Wikstrand J, Wendelhag I, Tengborn L, Fagerberg B. Femoral artery wall morphology, haemostatic factors and intermittent claudication: an ultrasound study in hypertensive and normotensive men. Haemostasis 1996; 26: 45-57.
10. 10 Agewall S, Wikstrand J, Fagerberg B. Prothrombin fragment 1+2 is a risk factor for acute coronary syndrome in treated hypertensive men. J Hypertens 1998; 16: 537-41.
11. 11 Laakso M, Sarlund H, Salonen R et al. Asymptomatic atherosclerosis and insulin reistance. Arterioscler Thromb 1991; 11: 1068-76.
12. 12 Agewall S, Fagerberg B, Attvall S, Wendelhag I, Urbanavicius V, Wikstrand J. Carotid artery wall intima-media thickness is associated with insulin-mediated glucose disposal in men at high and low coronary risk. Stroke 1995; 26: 956-60.
13. 13 Juhan-Vague I, Alessi MC, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 1996; 28: 371-80.
14. 14 Mansfield MW, Heywood DM, Grant PJ. Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM. Circulation 1996; 94: 2171-76.
15. 15 Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo-and hypertriglyceridaemic men. Diabetologia 1993; 36: 817-25.
16. 16 Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE. The cardiovascular risk factor plasminogen activator inhibitor 1 activity is related to insulin resistance. Metabolism 1993; 42: 945-49.
17. 17 Agewall S, Samuelsson O, Andersson OK, Persson B, Wikstrand J, Fagerberg B. The efficacy of multiple risk factor intervention in treated hypertensive men, during long term follow-up. J Int Med 1994; 236: 651-59.
18. 18 WHO Study Group. Diabetes Mellitus. Technical Report Series 646. Geneva: World Health Organization, 1980.
19. 19 Wilhelmsen L, Berglund G, Elmfeldt D et al. The multifactor primary prevention trial in Göteborg, Sweden. Eur Heart J 1986; 7: 279-88.
20. 20 Suurküla M, Agewall S. Fagerberg B, Wendelhag I, Widgren B, Wikstrand J. Ultrasound evaluation of atherosclerotic manifestations in the carotid artery in high-risk hypertensive patients. Arterioscler Thromb 1994; 14: 1297-304.
21. 21 Beckman Suurküla M, Wikstrand J, Berglund G, Sivertsson R. Body weight is more important than family history of hypertension for left ventricular function. Hypertension 1991; 17: 661-68.
22. 22 Nilsson IM, Olow B. Determination of fibrinogen and fibrinogenolytic activity. Thromb Diath Haemorrh 1962; 8: 297-309.
23. 23 Ferrannini E, Buzzigoli G, Bonadonna R et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-57.
24. 24 Forbes GB, Gallup J, Hursh JB. Estimation of total body fat from potassium-40 content. Science 1961; 133: 101-102.
25. 25 Ernst E, Koenig W, Lowe GDO, Meade TW, eds. Fibrinogen: a New Cardiovascular Risk Factor Vienna: Blackwell MZV, 1992.
26. 26 Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen-activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med 1990; 227: 273-78.
27. 27 Valek J, Valkova L, Vlasakova Z, Topinka V. Increased fibrinogen levels in the offspring of hypertensive men. Arteriscler Thromb Vasc Biol 1995; 15: 2229-33.
28. 28 Bloom AL. The biosynthesis of factor VIII. Clin Haematol 1979; 8: 53-77.
29. 29 Pedrinelli R, Giampietro O, Carmassi F et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344: 14-18.
30. 30 Ross R. The pathogenesis of atherosclerosis - an update. N Engl J Med 1986; 314: 488-500.
31. 31 Jensen-Urstad KJ, Reichard PG, Rosfors JS, Lindblad LEL, Jensen-Urstad MT. Early atherosclerosis is retarded by improved long-term blood glucose control in patients with IDDM. Diabetes 1996; 45: 1253-58.
32. 32 Groop L, Ekstrand A, Forsblom C et al. Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 642-47.
33. 33 Agewall S, Fagerberg B, Attvall S et al. Microalbuminuria, insulin sensitivity and haemostatic factors in non-diabetic treated hypertensive men. J Int Med 1995; 237: 195-203.
34. 34 Davi G, Gennaro F, Spatola A et al. Thrombin-antithrombin III complexes in type II diabetes mellitus. J Diab Comp 1992; 6: 7-11.
35. 35 Fernandez-Castaner M, Camps I, Fernandez-Real JM, Domenech P, Martinez-Brotons F. Increased prothrombin fragment 1 + 2 and D-dimer in first-degree relatives of type 2 diabetic patients. Prethrombotic state in relatives of type 2 diabetic patients. Acta Diabetologica 1996; 33: 118-21.
36. 36 Faccini FS, Hollenbeck CB, Jeppesen J, Chen YDI, Reaven GM. Insulin resistance and cigarette smoking. Lancet 1992; 339: 1128-30.
37. 37 Lithell H. Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care 1991; 14: 203-209.
38. 38 Alberti KGMM. Jones IR, Laker MF, Swai ABM, Taylor R. Effect of bezafibrate on metabolic profiles in non-insulin-dependent diabetes mellitus. J Cardiovasc Pharmacol 1990; 16(suppl. 9): S21-25.